...
首页> 外文期刊>BMC Infectious Diseases >Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana
【24h】

Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana

机译:博茨瓦纳怀疑耐药结核病患者多药/利福平抗性结核病患病率和因素

获取原文
           

摘要

To investigate the prevalence and factors associated with the prevalence of multidrug/rifampicin-resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana. A retrospective review of medical records of suspected drug resistant tuberculosis patients receiving care at public health facilities in Botswana was conducted from January, 2013 and December, 2014. Patient characteristics and drug susceptibility data were abstracted from 2568 medical records on to a pre-tested checklist form. The prevalence of multidrug/rifampicin resistance was computed. Bivariate and multivariate logistic regression was carried out to determine the factors associated with the prevalence of multidrug/rifampicin in the study population. Overall, multidrug/ rifampicin - resistance among suspected drug resistant tuberculosis patients in Botswana were found in 139 (5.4%) cases with 1.3% among new cases and 7.7% among previously treated tuberculosis patients. Being a previously treated tuberculosis patient and having a positive smear were found to be factors associated with the prevalence of multidrug/rifampicin-resistant tuberculosis (p??0.05). This study highlights a low burden of multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients receiving care at public health facilities in Botswana. Strategies in controlling MDR/RR-TB should emphasize on effective implementation of Directly Observation Treatment - short course strategy, continuous surveillance of drug resistance cases, prevention of the development of new cases of MDR/RR-TB and to treat existing patients. Further interventions should focus on strengthening TB infection control activities.
机译:探讨与博茨瓦纳怀疑耐药结核病患者的多药物/利福平抗性结核病患病率相关的患病率和因素。 2013年和12月在2014年和12月,对博茨瓦纳公共卫生设施接受护理的疑似耐药结核病患者的疑似耐药结核病患者的回顾性审查。患者特征和药物易感性数据从2568名医疗记录提取到预先测试的清单形式。计算多药/利福平抗性的患病率。进行了双变量和多变量的物流回归,以确定与研究人群中多药物/利福平的患病率相关的因素。总体而言,在博茨瓦纳的疑似耐药结核病患者之间的多药/利福平耐药性在139名(5.4%)病例中被发现,新病例中的1.3%,以前治疗的肺结核患者中有7.7%。被发现是先前治疗的结核病患者并发现阳性涂片是与多药物/利福平抗性结核分枝杆菌的患病率相关的因素(p ?? 0.05)。本研究突出了诸如博茨瓦纳公共卫生设施接受护理的疑似耐药结核病患者的多药/利福平抗性结核患者的低负担。控制MDR / RR-TB的战略应强调有效实施直接观察治疗 - 短程策略,耐药病例的连续监测,预防MDR / RR-TB的新病例和治疗现有患者。进一步的干预措施应专注于加强TB感染控制活动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号